8-K
filed May 22, 2023, 7:59 PM ET
ticker AYTU
CIK 0001385818
other material
confidence high
sentiment neutral
materiality 0.10
AYTU Biopharma stockholders approve 2023 equity incentive plan and elect all director nominees
AYTU BIOPHARMA, INC
- All five director nominees elected; For votes ranged 673,707–685,411, Withheld 304,133–315,837.
- 2023 Equity Incentive Plan approved: 632,357 For, 352,359 Against, 4,828 Abstain; 952,620 broker non-votes.
- Ratification of Grant Thornton as independent auditor approved: 1,754,922 For, 132,135 Against, 55,107 Abstain.
- Advisory vote on executive compensation approved (non-binding): 587,253 For, 383,698 Against, 18,593 Abstain.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
AYTU BIOPHARMA, INC shareholders approved Advisory vote on executive compensation at the 2023-05-18 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-05-18
Exact text from the filing
The advisory vote on executive compensation was approved with 587,253 votes in favor, 383,698 votes against and 18,593 abstentions. There were 952,620 broker non-votes.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
AYTU BIOPHARMA, INC shareholders approved Election of five directors at the 2023-05-18 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-05-18
Exact text from the filing
Our stockholders elected five members to our board of directors as follows:
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
AYTU BIOPHARMA, INC shareholders approved Ratification of the appointment of Grant Thornton, LLC as independent registered public accounting firm at the 2023-05-18 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-05-18
Exact text from the filing
The ratification of the appointment of Grant Thornton, LLC as the Company's independent registered public accounting firm for the fiscal year ending June 30, 2023 was approved with 1,754,922 votes in favor, 132,135 votes against and 55,107 abstentions.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
AYTU BIOPHARMA, INC shareholders approved Approval of the 2023 Equity Incentive Plan at the 2023-05-18 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-05-18
Exact text from the filing
The approval of a new equity incentive plan for certain officers, directors, employees and other key personnel, the “2023 Equity Incentive Plan” was approved with 632,357 votes in favor, 352,359 votes against, and 4,828 abstentions. There were 952,620 broker non-votes.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.